cyrilzakka/clinical-trials huggingface dataset:
Evaluation of Effect of Platelet-Rich Fibrin on Orthodontic Tooth Movement: a Split Mouth Randomised Controlled Trial

it is a randomized control trial and aims at investigating the effects of PRF on rate of tooth movement and root length to be tested on larger sample size of pakistani population


Eligibility Criteria:
Inclusion Criteria:

* Patients who give written consent to participate in the research
* Orthodontic patients with good oral hygiene
* Patients with periodontal probing depths≤3 mm with no bone loss
* Patients undergoing orthodontic treatment with fixed appliance and requiring upper first premolar extraction followed by canine retraction
* Patients treated with canine retraction utilizing maximum anchorage in the maxillary arch from trans-palatal arch anchorage device
* Patients with mild to moderate crowding in maxillary arch
* Patients with no previous history of orthodontic treatment

Exclusion Criteria:

* patients who are smokers, health compromised (such as diabetics, with bone disorders, immunocompromised, known with blood dyscrasias) will be excluded from the trial. Patients with drug history of non-steroidal anti-inflammatory drugs, anti-inflammatory (in last 30 days), antibiotic therapy in last 3 months and those women who are pregnant will also be excluded.

Other exclusion criteria will be patients with hypodontia, impacted/ectopic canines, extracted first molars, and patients who may discontinue the trial with or without assigning any reasons and those not consenting to participate in the research.
Detecting Acetabulum Movement After Total Hip Arthroplasty From Serial Plain Radiographs

This study mainly measures the orientation of acetabulum cup post total hip arthroplasty. Using "Liaw's Version", a new and accurate standardization method, investigators are trying to analyze acetabulum cup anterversion change postoperatively.

Patients undergoing total hip arthroplasty have generally good prognosis. However, clinically there was still a minority of patients who suffered from persistent postoperative pain. Dislocations of hip leading to revision surgeries were as well observed in some patients.

This study mainly measures the orientation of acetabulum cup post total hip arthroplasty. Using "Liaw's Version", a new and accurate standardization method, investigators are trying to analyze acetabulum cup anterversion change postoperatively.

As previously known, the anteversion of acetabulum cup determines the range of motion, stability, and the function after total hip arthroplasty. Cup malalignment increase impingement, dislocation, cup migration, and polyethylene wear. Finding a pattern may help the early diagnosis of acetabular loosening.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergone total hip arthroplasty
* Patients undergone total hip arthroplasty with more than two postoperative X-ray plain films

Exclusion Criteria:

* Patients with postoperative periprosthetic fracture(s)
* Patients with postoperative infection
* Patients undergone revision total hip arthroplasty
Evaluation of Lung Atelectasis During Apneic Oxygenation Using THRIVE in Adults During Laryngeal Surgery.

Oxygenation with high-flow nasal cannula with 100% oxygen have now been evaluated in a number of studies and the data are convincing. The THRIVE technique is able to oxygenate patients safely and vital parameters has been shown to be stable. But it is of great importance to evaluate this new concept regarding other potential negative physiological aspects such as lung atelectasis and inflammatory stress response before implementing it into clinical practice.


Eligibility Criteria:
Inclusion Criteria:

1. Adults, \>18 years old.
2. ENT-surgery where apnea is of benefit for the surgeon (eg. intraoral or laryngeal surgery).
3. Capable of understanding the study information and sign the written consent.

Exclusion Criteria:

1. ASA\>2
2. NYHA \>2
3. Pacemaker or ICD.
4. BMI \>35
5. Pregnancy
6. Manifest cardiac failure or coronary disease
7. Severe gastrointestinal reflux.
8. Neuromuscular disorder
The Effect of Adding Either Propofol or Ketamine to Magnesium and Lidocaine Infusions in Nasal Surgeries.

Nasal surgeries are common day case procedures. Although surgical complications are rare, bleeding decreases surgical field visibility and may cause vascular, orbital or intracranial complications in addition to failure of procedure. So, it is crucial to maintain hypotensive anaesthesia to optimize the surgical field.

In this study the investigators compare the effect of; propofol- lidocaine-magnesium and ketamine- lidocaine- magnesium infusions to dexmedetomidine- lidocaine- magnesium infusion on surgical field quality, intraoperative haemodynamics, surgical time, recovery time, sedation score, time to first rescue analgesic and incidence of PONV in patients undergoing nasal surgeries

Eligibility Criteria:
Inclusion Criteria:

* ASA I-II,
* scheduled for elective nasal surgery

Exclusion Criteria:

* Patients with uncontrolled hypertension.
* Patients with cardiac disease.
* Patients with renal, hepatic or cerebral insufficiency.
* Patients with coagulopathy or receiving drugs influencing blood coagulation.
* Anaemia, haemoglobinopathies or polycythemia.
* Pregnancy.
* Patients with known sensitivity to any of the study drug.
Gingival Clefts and Orthodontic Movement

Clefts or invaginations of the gingival tissue are a frequent finding during orthodontic space closure after extraction of a tooth. They occur in about 35% of the cases. Increased risk of developing a gingival cleft is given in the mandibular arch. A gingival invagination impairs aesthetics, orthodontic treatment and periodontal health. The aim of this prospective split-mouth designed observer blinded study is to evaluate possible differences between tooth movement in recent or in healed extraction sockets on incidence of gingival clefts. We hypothesize, that similar to the results originated from an animal study immediate movement in extraction sockets reduces incidence of gingival clefts during orthodontic space closure.


Eligibility Criteria:
Inclusion Criteria:

* extraction of both molars or premolars in the upper or lower jaw and orthodontic space closure

Exclusion Criteria:

* periodontal status not allowing orthodontic treatment
A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women with Osteoporosis After a Treatment Period Without Fractures

The goal of this clinical trial is to study the effects of discontinuation of Alendronate treatment for three years. The participants are postmenopausal women with osteoporosis, who have had a treatment period without fractures. The study will answer:

* What is the rate of fragility fractures during the study? The hypothesis is that discontinuation of Alendronate after a fracture-free period does not raise the 3-year fracture risk.
* Are there predictors of significant bone loss after discontinuation of Alendronate? The hypothesis is that clinical, biochemical, cellular, or molecular characteristics can predict bone loss.

Researchers will compare the outcomes of discontinuation of Alendronate with continuing treatment. Participants will be randomly assigned to a group.

Participants will:

* Either take alendronate once weekly for three years OR discontinue their treatment
* Visit the clinic at 6 and 18 months for blood samples
* Visit the clinic at the start of the study and after 1, 2, and 3 years for bone scans and blood samples.


Eligibility Criteria:
Inclusion Criteria:

* Female
* Postmenopausal
* Current treatment with Alendronate
* Alendronate treatment \>3 år AND no fracture OR
* Alendronate treatment \>5 år AND latest low energy fracture \> 3 years ago

Exclusion Criteria:

* T-score \< - 3,5 in hip (total hip or femoral neck) or lumbar spine
* Treatment with systemic glucocorticoids, ongoing or within 12 months
* Uncontrolled inflammatory disease
* Active malignancy
* eGFR \< 40 mL/min
* Atypical femur fracture (ever)
* OsteoNecrosis of the Jaw (active)
* Unable to give inform consent
Preoperative Condition in Giant Obese Patients

The frequency of super-super obese who need immediate weight loss surgery is risen continuously. For those patients a prior-to-surgery conditioning therapy is mandatory to gain technical and physical operability. The exclusively well-established preliminary therapy so far was the intragastric balloon, which takes 7 months of treatment time. Due to life-threatening conditions of giant obese patients, who have been admitted to hospital, the investigators were forced to develop a more prompt acting conditioning therapy to bring those individuals in a short run to an improved and "fit-for-surgery" state. In such an impasse the investigators combine Liraglutide with its well-known weight-loss effect with a leucine-based amino acid infusion that is generally used for patients with liver insufficiency, in expectance of an additional weight loss and liver reduction effect.

The investigators will use a commercial available amino acid infusion (Aminosteril hepa 8%, Fresenius Karbi), which is used in clinical application for liver conditioning. It is mainly based on the branched-chained amino acid leucine (13.09 g per 1000 ml). The investigators will combine this with a daily subcutaneous injection of Liraglutide. Liraglutide is a GLP-1 analogue, which achieved meanwhile the FDA approval for weight loss treatment. Initial Liraglutide dosage is 1.2 mg for three days, boosted to 1.8 mg consecutively. Participants receive energy reduced nutrition with 1000 kcal/d.

Eligibility Criteria:
Inclusion Criteria:

* multimorbid, super-super obese patients

Exclusion Criteria:

* renal insufficiency III
A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)

A clinical study to evaluate the efficacy and safety of MK0633 in patients with Chronic Obstructive Pulmonary Disease (COPD).


Eligibility Criteria:
Inclusion Criteria:

* Documented COPD defined by clinical history and spirometry, with symptoms including dyspnea, wheezing, chest tightness, cough, sputum production, or nocturnal awakening
* Male or postmenopausal females 40 -75 years of age

Exclusion Criteria:

* Impaired renal function
* History of chronic liver disease or persistent liver function test (LFT) abnormalities
* History of recent cardiovascular clinical event
* Evidence of another clinically significant, active pulmonary disorder such as bronchiectasis or asthma
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

This trial will be initiated to explore whether RBX2660 (REBYOTA®) could be suitable for administration by the practice of colonoscopy. More specifically, the purpose of this trial is to explore the safety and clinical effectiveness of RBX2660 when delivered by colonoscopy to adults with rCDI. The experience of physicians will be documented through a physician-experience questionnaire to explore the usability of RBX2660 in clinical practice for colonoscopic administration. Furthermore, to explore the patient-experience of RBX2660 treatment, each trial participant will be offered to undergo a structured interview.


Eligibility Criteria:
Inclusion Criteria:

* have documented evidence of rCDI (≥1 recurrence after a primary CDI episode)
* be undergoing antibiotic treatment for the qualifying rCDI episode that was diagnosed by a stool test for the presence of toxigenic C. difficile or C. difficile toxin
* be eligible for FMT as judged by the investigator or current treatment guidelines for rCDI in the US
* be a candidate for colonoscopy as judged by the investigator

Exclusion Criteria:

* Use or planned use of systemic antibiotics for an indication other than the qualifying rCDI episode.
* Current uncontrolled chronic diarrhea not related to CDI.
* Receipt of CDI vaccine or treatment with CDI monoclonal antibodies within the past 12 months before screening.
* Evidence of active, severe, or fulminant colitis, diagnosis of toxic megacolon or have a current colostomy or ileostomy
Effects of Different Exercise Programs for People With Chronic Whiplash Associated Disorders

Background:

Costs of health care consumption and sick leave 2006 in Sweden for Whiplash Associated Disorders (WAD) was estimated to be 4 billion Swedish crowns. Despite tremendous costs and personal sufferings there are only a few prospective randomized studies (RCT) in patients with chronic WAD, and none of them evaluating return to work, or the role of neck specific exercises with or without a combination of a behavioral approach compared with prescribed physical activity.

Aim:

The general aim of this RCT is to examine what neck-specific training with or without a combination with behavioral approach adds to prescribed physical activity of persons with chronic WAD with regard to pain intensity, physical and psychological function, health care consumption and return to work. Another aim is to study predictive factors of importance for a good outcome of rehabilitation.

Method:

After informed consent patients in age 18-63 years of age with WAD II-III with more than 6 months duration will be randomized to one out of the three alternatives of physiotherapy, treatment with medical exercise therapy with neck specific exercises (A),treatment with a behavioral approach combined with neck specific exercises (B), prescribed physical activity (C). Randomisation will be done by the central project leader. 200 patients will be included in the study. All physiotherapists engaged in the structured and well described treatment will be introduced in the program by the project leader. The measurements with good clinometric properties will be performed before treatment, after 12 weeks, 6, 12 and 24 months after inclusion into the study. Clinical measurements will be performed by a blinded investigator. Background data, disease-specific and generic data will be measured by self-evaluated answered questionnaires by the patients. Days of sick-leave will be collected from the Social Insurance Agency. Main outcomes of the measurements are pain intensity, neck specific disability and return to work. Cost-effectiveness will be calculated.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-63 years
* WAD II-III
* Remaining problems (\>10mm on 100mm Visual Analogue Scale (VAS) or \>20% on Neck Disability Index (NDI) or at least moderate pin on NDI) at least 6 months but no more than 3 years after whiplash trauma

Exclusion Criteria:

* Myelopathy
* Earlier fracture or luxation of the cervical column, earlier neck injury
* Spinal tumour
* Spinal infection
* Surgery in the cervical column
* Malignity
* Systematic disease or another injury contraindicated to perform the treatment program or the measurements.
* Diagnosed severe psychiatric disorder
* Unconscious in connection to the trauma
* Known drug abuse
* Lack of familiarity with the Swedish language
A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

This study will investigate the safety and efficacy of an investigational drug, PF-04171327 on the signs and symptoms of rheumatoid arthritis in patients that require glucocorticoids while on background methotrexate. This study will also look at the response of chemical and biological markers in rheumatoid arthritis patients. Lastly, this study will measure the PK (amount of drug in the blood) of methotrexate while patients may be taking PF-04171327.


Eligibility Criteria:
Inclusion Criteria:

* Patients ≥ 18 years of age, diagnosed with rheumatoid arthritis for a minimum duration of 3 months
* On stable dose of methotrexate for at least 6 weeks prior to screening
* Patient must have minimum disease activity level of ≥ 6 tender/painful joints, ≥ 6 swollen joints and CRP ≥ 0.7 mg/dL
* Not currently receiving steroid medication

Exclusion Criteria:

* Pregnant or nursing women
* Patients that have active infections, TB, HIV and/or Hepatitis B or C
* Patients that have a history of intolerance or significant adverse effects with the use of glucocorticoids
A Study on Relationship Between Resected Normal Liver Parenchymal Volume（RNLV）and Post-Hepatectomy Liver Failure (PHLF)

The post-hepatotectomy liver failure (PHLF) is still the most worrisome complication of hepatic resection. Surgeons have always been making efforts to preoperatively predict PHLF using kinds of techniques, scoring systems, and variables. The investigators of this study tried to create an individual predictive model based on the variable, resected normal parenchymal volume (RNLV), then assessing the performance and value of the model in clinical practice.

The investigator launched a large sample-size and retrospective study, enrolling more than a thousand consecutive patients diagnosed with hepatocellular carcinoma (HCC) and intracholangiocarcinoma (ICC) underwent hepatotectomy from the investigator's center. The primary aim of study was to identify whether there was strong correlation between RNLV and PHLF, and the second aim was to further build a combination model based on RNLV and evaluate the value of predicting PHLF in clinical practice. The investigators attached same importance to RNLV, compared to future liver remnant, especially for patients with massive tumors and multiple tumors. The investigators hyperthesized that RNLV could be an indicative variable for surgical safety, and help to form a diversifying method to comprehensively assess the risk of PHLF preoperatively.

Eligibility Criteria:
Inclusion criteria:

* selective hepatectomies;
* histologically confirmed as HCC and ICC
* complete and accessible data

Exclusion criteria:

* any history of Associated Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS)
* any history of portal vein embolism (PVE)
* any history of tumor rupture
* emergency surgery
* pathologically diagnosed with neither HCC nor ICC
* concomitant resection of gastrointestinal organs, spleenectomy or other organs
Effects of Cholinergic Augmentation on Measures of Balance and Gait

This study will compare the effects of placebo and donepezil, a drug that helps conserve concentrations of the neurotransmitter, acetylcholine, on measures of balance and gait in subjects with Parkinson's disease (PD). This study is a double-blind, placebo controlled, cross-over randomized clinical trial. Short-latency afferent inhibition (SAI), a physiological index of cholinergic function will be measured to determine if the deficits in balance and gait correlate with abnormalities of the SAI and if SAI is altered by donepezil as a measure of drug efficacy. Cognitive tests like the Attention Network Test (ANT) will be administered to determine if changes in gait and balance are mediated by changes in attention.

The results of this study will be the most direct test of the hypothesized role of cholinergic neurons and the neurotransmitter, acetylcholine in terms of gait and balance. The study is exploratory because it is not known whether donepezil will affect gait, balance or attention, nor which measures of gait, balance or attention will be sensitive to drug manipulation. The study's immediate goal is to determine the potential utility of cholinergic manipulation as a strategy for preventing or treating balance and gait dysfunction in PD. The findings of this trial are intended to lead to more sharply focused questions about the role of cholinergic neurons in balance and gait and eventually to Phase II B trials to determine clinical utility of cholinergic manipulation to prevent falls and improve mobility.


Eligibility Criteria:
Inclusion Criteria:

* 30 years old or older
* Diagnosis of idiopathic Parkinson's disease
* Stand unassisted (without use of an assistance device) and walk continuously for at least 2 minutes.

Exclusion Criteria:

* musculoskeletal disorders that affect standing and walking
* Uncorrected vision disturbance
* Vestibular problems
* Major depression
* Hallucinations or other psychiatric disturbances
* Tachycardia
* Bradycardia
* Arrhythmias
* Peptic ulcer disease
* Use of anticholinergics
* Use of cholinesterase inhibitors
* Use of bladder antispasmodics
* Use of tricyclic antidepressants
Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy. SNORE Study (P05155)

The purpose of this study is to determine whether 8 weeks treatment with mometasone furoate nasal spray (MFNS), twice daily, is safe and effective in treating adenoid hypertrophy in children.


Eligibility Criteria:
Inclusion Criteria:

* Participants and their parents must demonstrate willingness to participate and comply with study procedures. Parents must sign a written informed consent
* Participants and their parents must understand and be able to adhere to dosing and visit schedules, and agree to record symptom severity scores, medication times, and concomitant medications accurately and consistently in a daily diary
* Children with a history of adenoid hypertrophy for at least 3 months with no response to previous medical treatment
* Baseline adenoid tissue size must have been graded by nasopharyngoscopy examination as Grade III or IV on the Adenoid/Choana (A/C) Index (between 50% and 100% obstruction)
* Baseline Total Severity Symptoms Score must be ≥ 8 points (AM or PM)
* For inclusion in endpoints relating to otitis media with effusion (OME), participant must have persistent middle ear effusion for the past 3 months or more documented by otoscopic examination, middle ear pressure less than -150 mm H2O, Jerger type B flat tympanogram, and mild-moderate conductive hearing loss in audiometry supporting the diagnosis of OME

Exclusion Criteria:

* Participants with previous surgery of hypertrophic adenoids with or without tympanostomy tube placement
* Participants treated with inhaled or systemic corticosteroids within the past 1 month
* Participants with Morbid Obesity (Body Mass Index \>95 percentile of charts from the Centers for Disease Control)
* Participants who have not accomplished the designated washout periods for any of the prohibited medications
* Participants who have used any investigational products within the last 30 days
* Participants who have used any antibodies for allergies in the past 90 days
* Participants who have any abnormal physical examination results that may affect study evaluations or participant safety in the investigator's judgment
* Participants who are allergic or have an idiosyncratic reaction to corticosteroids
* Participants with signs and symptoms of acute or chronic bacterial rhinosinusitis
* Participants has had an upper or lower respiratory tract or sinus infection that required antibiotic therapy with the last dose later than 14 days prior to screening, or who has had a viral upper or lower respiratory infection within 7 days prior to screening
* Participants with a documented immunodeficiency condition
* Participants with nasal structural abnormalities, including large nasal polyps and marked septum deviation that significantly interferes with nasal airflow
* Participants with any clinically significant metabolic, cardiovascular, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disease (other than asthma), or any other disorder which, in the judgment of the Investigator, may interfere with the study evaluations or affect participant safety